Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece

被引：0
|
作者：
Theodoros V. Giannouchos
Dimos-Dimitrios Mitsikostas
Robert L. Ohsfeldt
Athanassios Vozikis
Paraskevi Koufopoulou
机构：
[1] Texas A&M University,Department of Health Policy and Management, School of Public Health
[2] Texas A&M University,Population Informatics Lab
[3] National and Kapodistrian University of Athens,First Neurology Department, Aeginition Hospital, School of Medicine
[4] University of Piraeus,Laboratory of Health Economics and Management, Economics Department
[5] KAT General Hospital of Attica,undefined
来源：
Clinical Drug Investigation | 2019年 / 39卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：979 / 990
页数：11
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN FOR ADULTS WITH CHRONIC KIDNEY DISEASE (CKD) IN GREECE
    Koulentaki, M.
    Vlahakos, D.
    Tsimihodimos, V
    Smyrnaios, C.
    Delli, E.
    Karpouzos, G.
    Kourlaba, G.
    VALUE IN HEALTH, 2024, 27 (12) : S75 - S75
  • [32] Cost-Effectiveness of Erenumab and Surgical Trigger Site Deactivation in the Treatment of Migraine Headaches: A Systematic Review
    Shah, Nikhil D.
    Castro, Ruben
    Isfahani, Sanaz N. Attaripour
    Vyas, Raj M.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2021, 233 (05) : S205 - S205
  • [33] A COST-EFFECTIVENESS ANALYSIS OF TICAGRELOR IN PATIENTS WITH ACUTE CORONARY SYNDROME IN GREECE
    Kritikou, P.
    Yfantopoulos, J.
    VALUE IN HEALTH, 2011, 14 (07) : A379 - A379
  • [34] COST-EFFECTIVENESS ANALYSIS OF BIMEKIZUMAB IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS (AXSPA) IN GREECE
    Koulentaki, M.
    Ravanidis, S.
    Daoussis, D.
    Dimitroulas, T.
    Papagoras, C.
    Sfikakis, P.
    Kountouris, V
    Feretos, M.
    Kourlaba, G.
    Lyris, N.
    Willems, D.
    VALUE IN HEALTH, 2024, 27 (12) : S109 - S109
  • [35] A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy
    Wolters, Sharon
    Carpay, Johannes A.
    Pronk, Marja H.
    Zuurbier, Karin W. M.
    Driessen, Maurice T.
    Lyras, Leonidas
    Postma, Maarten J.
    BMC NEUROLOGY, 2024, 24 (01)
  • [36] Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine
    Lofland, JH
    Kim, SS
    Batenhorst, AS
    Johnson, NE
    Chatterton, ML
    Cady, RK
    Kaniecki, R
    Nash, DB
    MAYO CLINIC PROCEEDINGS, 2001, 76 (11) : 1093 - 1101
  • [37] COST-EFFECTIVENESS OF PONATINIB IN THE TREATMENT OF PATIENTS WITH CHRONIC PHASE- CHRONIC MYELOID LEUKEMIA IN GREECE
    Gourzoulidis, G.
    Kourlaba, G.
    Giannoulia, P.
    Panagiotidis, P.
    Maniadakis, N.
    VALUE IN HEALTH, 2017, 20 (09) : A435 - A435
  • [38] A Retrospective Analysis to Evaluate the Response of the Addition of Erenumab to OnabotulinumtoxinA for the Prevention of Intractable Chronic Migraine Without Aura
    Armanious, M.
    Jimenez-Sanders, R.
    HEADACHE, 2019, 59 : 166 - 167
  • [39] Effectiveness of erenumab in chronic migraine in a tertiary headache centre
    Khalil, Modar
    Moreno-Ajona, David
    Greenwood, Fiona
    Hoffmann, Jan
    Goadsby, Peter J.
    CEPHALALGIA, 2019, 39 : 269 - 270
  • [40] OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales
    Freemantle, Nick
    Khalaf, Kristin
    Loveman, Clara
    Stanisic, Sanja
    Gultyaev, Dmitry
    Lister, Johanna
    Drake, Marcus
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2016, 17 (07): : 911 - 921
12345